A randomized phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort Meeting Abstract
| Authors: | Okamoto, A.; Kim, J. W.; Yin, R.; Trillsch, F.; Reuss, A.; Aghajanian, C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Floquet, A.; Nyvang, G. B.; Colombo, N.; Bidzinski, M.; Marth, C.; Lheureux, S.; Van Nieuwenhuysen, E.; Rugman, P.; Wessen, J.; Harter, P. |
| Abstract Title: | A randomized phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort |
| Meeting Title: | 2022 Society of Gynecologic Oncology Annual Meeting |
| Journal Title: | Gynecologic Oncology |
| Volume: | 166 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Mar 18-21 |
| Meeting Location: | Phoenix, AZ |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-08-01 |
| Start Page: | S170 |
| Language: | English |
| ACCESSION: | WOS:000892330200221 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0090-8258(22)01551-7 |
| Notes: | Meeting Abstract: 329 -- Source: Wos |
